← Back to Search

Dental Health Assessment for Esophageal Cancer

N/A
Recruiting
Led By Steven Maron, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to understand why tooth enamel wears away in people with esophagogastric cancer & how often it occurs.

Who is the study for?
This study is for adults over 18 with esophagogastric cancer who can understand English or have translation services. They should be able to complete a survey and allow photos of their teeth, but those without teeth or major dental work on molars that affects enamel assessment cannot join.
What is being tested?
The study aims to understand tooth enamel loss in people with various cancers including esophagogastric cancer. Participants will provide saliva samples, answer surveys about their oral health, and have pictures taken of their teeth using an intra-oral camera.
What are the potential side effects?
Since this trial involves non-invasive procedures like surveys and taking pictures inside the mouth, there are no significant side effects expected from participating in this research.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The incidence of dental erosions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Patients diagnosed with esophagogastric cancerExperimental Treatment3 Interventions
Patients have completed the intervention once completing the survey, undergoing dental imaging and future patients will also provide an optional saliva sample.
Group II: Patients diagnosed with colorectal, pancreatic, breast, head and neck, or non-small cell lung cancerExperimental Treatment2 Interventions
Patients undergo consenting and dental imaging during their routine visits at MSK.
Group III: Healthy volunteers who have not been diagnosed with cancerExperimental Treatment2 Interventions
Healthy controls will be defined as those without a known or suspected invasive cancer history and excluding those undergoing a procedure for symptomatic reflux.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,538 Total Patients Enrolled
Steven Maron, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
25 Total Patients Enrolled

Media Library

Patients diagnosed with esophagogastric cancer Clinical Trial Eligibility Overview. Trial Name: NCT05612048 — N/A
Esophageal Cancer Research Study Groups: Patients diagnosed with esophagogastric cancer, Patients diagnosed with colorectal, pancreatic, breast, head and neck, or non-small cell lung cancer, Healthy volunteers who have not been diagnosed with cancer
Esophageal Cancer Clinical Trial 2023: Patients diagnosed with esophagogastric cancer Highlights & Side Effects. Trial Name: NCT05612048 — N/A
Patients diagnosed with esophagogastric cancer 2023 Treatment Timeline for Medical Study. Trial Name: NCT05612048 — N/A
~86 spots leftby Nov 2025